Vaxxinity Inc (VAXX) AI Stock Analysis

Vaxxinity Inc

(Other OTC:VAXX)

Select Model

Rating:26Underperform

Action:N/A

Date:01/02/25

Vaxxinity Inc's overall score reflects its severe financial difficulties, lack of technical analysis data, and poor valuation metrics. The company's high financial leverage, persistent losses, and cash flow challenges significantly weigh down the score. With no guidance or sentiment from recent earnings calls, there is little to offset these concerns.

Positive Factors

Innovative Vaccine PlatformVaxxinity's innovative platform for developing vaccines positions it well in the biotechnology sector, potentially transforming treatment landscapes for chronic diseases.

Negative Factors

High Financial LeverageHigh financial leverage can strain Vaxxinity's financial stability, increasing risk and potentially limiting its ability to invest in growth opportunities.

Vaxxinity Inc (VAXX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $11.29K
Dividend Yield: ―
Average Volume (3M): 924
Price to Earnings (P/E): -0.2
Beta (1Y): 486.54
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 57
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Vaxxinity Inc Business Overview & Revenue Model

Company Description

Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and...

How the Company Makes Money

Vaxxinity Inc generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to advance its pipeline of vaccine products through clinical trials and regulatory approvals, ultimately leading to co...

Vaxxinity Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

VAXX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GRI	58Neutral	$3.34M	-0.04	-134.03%	―	―	93.96%
EVAX	52Neutral	$24.44M	-0.48	-61.39%	―	134.15%	82.33%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	41Neutral	$268.82K	0.00	-26.63%	―	30.12%	-165.46%
AIM	40Underperform	$6.16M	-0.04	952.76%	―	-21.49%	84.62%
VAXX	26Underperform	$14.07K	-0.20	-0.15%	―	―	―

* Healthcare Sector Average

Performance Comparison

VAXX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
VAXX	Vaxxinity Inc	0.03	0.01	35.00%
AIM	Aim Immunotech Inc.	0.15	-1.85	-92.33%
SCNI	Scinai Immunotherapeutics Ltd. Sponsored Adr	0.47	-12.23	-96.29%
EVAX	Evaxion Biotech A/S Adr	2.93	-2.84	-49.22%
GRI	Gri Bio, Inc.	1.53	-43.27	-96.58%
CDT	Cdt Equity Inc.	0.07	-15624.93	-100.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 02, 2025

Vaxxinity Inc AI Stock Analysis